COMMITMENTS AND CONTINGENCIES (Details Narrative)		3 Months Ended		9 Months Ended
	May 31, 2023	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 AUD ($)	Dec. 31, 2023 USD ($)
Property, Plant and Equipment [Line Items]
Accrued liabilities		$ 253,150		$ 253,150			$ 1,075,643
Accounts payable		576,324		576,324			1,218,783
Research and development expenses		(762,717)	$ (1,281,455)	(1,736,373)	$ (5,531,436)
Research and development expenses		762,717	1,281,455	1,736,373	5,531,436
Research and development expense tax credit receivable							145,349
Future cash		3,111,683		3,111,683			$ 2,287,977
Reduction in force restructuring percentage	35.00%
Other Consulting and Vendor Agreements [Member]
Property, Plant and Equipment [Line Items]
Future cash		100,000		100,000
Avance Clinical [Member]
Property, Plant and Equipment [Line Items]
Contract cost		2,329,000		2,329,000		$ 3,400,000
Prepaid assets		0		0
Accrued liabilities		0		0
Accounts payable		0		0
Research and development expenses		(264,385)	(157,117)	(508,774)	(401,284)
Research and development expenses		$ 264,385	$ 157,117	$ 508,774	$ 401,284